Company Overview and News

 
Mount Ridley Mines is ready to pounce

2017-12-10 proactiveinvestors.com.au
Mount Ridley Mines Ltd (ASX:MRD) has an acquisition on the table, and the ASX has granted the company a trading halt to prepare details.

 
Mount Ridley Mines is ASX Volume Leaders at the close

2016-10-12 proactiveinvestors.com.au

 
Mount Ridley Mines to reveal exploration update

2016-10-09 proactiveinvestors.com.au
Mount Ridley Mines Ltd (ASX:MRD) has been granted a trading halt by the ASX this morning, with its shares placed in pre-open.

 
Mount Ridley Mines Ltd explores for nickel copper sulphides in Albany-Fraser Range

2016-07-25 proactiveinvestors.com.au
Mount Ridley Mines Ltd (ASX:MRD) has re-commenced a program of deep diamond drilling at Target 19, Mt Ridley Project in the Albany-Fraser Range Province in Western Australia. Drilling in hole MRDD015 had earlier intersected a discontinuous 180 metre thick zone of minor (1-3%) disseminated nickel and copper sulphides from 470 metres. This was short of the planned 800 metre target depth. The interpretation was that this could represent a halo surrounding a more substantial accumulation of sulphides nearby.

 
Change in substantial holding

2016-04-21 asx.com.au

 
Change in substantial holding

2016-04-21 asx.com.au

 
 
Placement of Shares

2016-04-12 asx.com.au

 
Mount Ridley Mines Ltd raising funds for Fraser Range nickel

2016-04-08 proactiveinvestors.com.au
Mount Ridley Mines Ltd (ASX:MRD) is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare. Last month the company identified new massive nickel sulphide potential at the wholly-owned Mt Ridley Project in the Albany-Fraser Range Province. The halt will remain in place until the opening of trade on Tuesday 12th April 2016, or earlier if an announcement is made to the market.

 
Mount Ridley Mines Ltd raising funds, nickel potential in Fraser Range

2016-04-08 proactiveinvestors.com.au
Mount Ridley Mines Ltd (ASX:MRD) is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare. Last month the company identified new massive nickel sulphide potential at the wholly-owned Mt Ridley Project in the Albany-Fraser Range Province. The halt will remain in place until the opening of trade on Tuesday 12th April 2016, or earlier if an announcement is made to the market.

 
Trading Halt

2016-04-08 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...